Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Roche’s Vismodegib Meets Main Goal of Advanced Skin-Cancer Study

Don't Miss Out —
Follow us on:

Sept. 24 (Bloomberg) -- Roche Holding AG’s experimental vismodegib treatment helped patients with a form of skin cancer known as advanced basal cell carcinoma, according to a study presented today at the European Multidisciplinary Cancer Congress in Stockholm.

The drug shrunk tumors and healed lesions in patients whose cancer had progressed too far to be removed with surgery, Roche said in a statement Sept. 12.

To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.